Quality, Not Volume
Sabil Health is not a marketplace. We don't blast deal flow or sell databases. We qualify both sides, score compatibility, and facilitate introductions only when there's a genuine fit. Here's how.
Behind every match
Human expertise, not just algorithms
Every application is reviewed by a domain expert before any match is made.
Jamil Hallak
Co-Founder — Financial & Structural Lead
Valuation · Deal Structure · Fund Terms · Mandate Fit
25+ years in global capital markets. Currently CIO at Othaim Holding Company (Riyadh). Former SVP Head of Investments at Riyad Bank, Head of MENA & Africa EM Trading at Deutsche Bank, and senior roles at BNP Paribas, Standard Chartered, Credit Suisse, and Société Générale. Sorbonne + Cass Business School MBA.
Mohamed Chekoua
Co-Founder — Technical & Sectoral Lead
Regulatory · IP · Clinical Stage · Competitive Landscape
Doctor of Pharmacy and Sciences Po Paris graduate. Chief of Staff to the President of France Biotech (700+ startups & funds). Formerly in the cabinets of two French Ministers of Health. Strategy consultant in London. Founder of Pharm6 — France's most-followed pharma media outlet, 3,500+ newsletter readers at 63% open rate.
Apply
3-minute application. Stage, focus, capital needs, geography.
Get Qualified
Our team verifies every applicant. Only serious parties enter.
Receive Matches
Scored anonymized memos. Only the right opportunities, not all of them.
Connect
Both sides confirm interest. NCA signed. Introduction made.
What Investors Receive
Every qualified opportunity arrives as a confidential investment memo — scored across 10 factors, verified by two experts.
CONFIDENTIAL INVESTMENT MEMO
SH-INN-2026-00047
Vertical
Biotech
Stage
Phase II
Country
France
Raising
€15M
Summary
Clinical-stage biotech developing a first-in-class oral therapy for a large inflammatory disease indication. Phase II data showed statistically significant efficacy (p<0.001). Strong IP portfolio with 12 granted patents. Experienced management team with 2 prior exits. Seeking Series B to fund Phase III.
Compatibility Breakdown
Identity revealed only after mutual interest + NCA
What Startups & Funds Receive
When an allocator matches your profile, you receive a scored interest memo — verified mandate, ticket size, and compatibility breakdown.
ALLOCATOR INTEREST MEMO
SH-ALC-2026-00012
Type
Multi-Family Office
Country
Saudi Arabia
Ticket
€2M – €10M
Sectors
Biotech, Medtech
Mandate Summary
Seeking Series A–B healthcare companies in Europe with strong IP and clinical data. Preference for biotech and medtech with clear regulatory pathways. Open to co-investment. Time horizon: 5–7 years. Actively deploying from a €120M healthcare allocation.
Compatibility Breakdown
Identity revealed only after mutual interest + NCA
Ready to Get Started?
Whether you're building the next breakthrough or looking to invest in one, it starts with a three-minute application.